Skip to main content
DrugPrice

Exclusivity Period

A period of market protection granted by the FDA (separate from patents) during which generic competitors cannot be approved, even if no patent exists.

How It Works

FDA exclusivity is a statutory protection independent of patent law, administered under the FD&C Act and its amendments. Key exclusivity types: (1) New Chemical Entity (NCE) exclusivity, 5 years for novel molecules, blocks ANDA filing for 4 years and approval for 5; (2) New Clinical Investigation exclusivity, 3 years for new uses, formulations, or studies requiring clinical investigation; (3) Orphan Drug Exclusivity, 7 years under the Orphan Drug Act of 1983 for drugs treating diseases affecting under 200,000 Americans; (4) Pediatric Exclusivity under BPCA, 6 months added to all existing patents and exclusivities in exchange for pediatric clinical studies; (5) Qualified Infectious Disease Product (QIDP) exclusivity, 5 additional years under the GAIN Act (2012) for antibiotics treating serious infections; (6) Reference Product exclusivity for biologics under BPCIA, 12 years from licensure (4-year biosimilar filing bar, 12-year approval bar). Exclusivity periods are listed in the Orange Book (small molecules) and Purple Book (biologics). Crestor got a 6-month pediatric extension in 2016, pushing generic entry from November 2015 to May 2016. Revlimid's orphan drug exclusivity expired before its composition patent, so patent life dominated. Biologic 12-year exclusivity has been criticized as excessively long compared to the 8-year standard in the EU and 5-year patent equivalent for small molecules; the IRA did not shorten BPCIA exclusivity but did include biologics in negotiation eligibility starting 11 years post-approval.

Related Terms

  • Patent Expiration, The date when a drug's patent protection ends, allowing generic or biosimilar manufacturers to produce competing versions.
  • FDA Approval, The process by which the U.S. Food and Drug Administration evaluates a drug's safety and efficacy through clinical trial data before allowing it to be marketed.
  • Abbreviated New Drug Application (ANDA), The FDA application pathway for generic drugs, which requires proving bioequivalence to the brand-name drug rather than repeating full clinical trials.
  • Reference Product, The FDA-licensed biologic against which a biosimilar is compared and approved under BPCIA, equivalent to the brand-name innovator biologic.

Explore Drug Data

Most Expensive DrugsGeneric Drug WatchSearch All Drugs

About This Definition

This definition is part of the DrugPrice Drug Pricing Glossary, 49 terms explaining how prescription drug pricing works in the United States. All definitions are written in plain language for patients, caregivers, journalists, and healthcare professionals.

this entity is one of the U.S. Medicare prescription-drug pricing concepts that recurs across this site. The definition above is the technical answer; the paragraphs below add the practical context for how the concept connects to the CMS Medicare Part D Drug Spending data data behind every per-entity page on the site.

In the CMS Medicare Part D Drug Spending data data, this concept shapes one or more of the fields that drive the per-entity grades and rankings on this site. The methodology page describes which fields feed into which output; this glossary entry documents the underlying term.

Source: CMS Medicare Part D Spending, 2026.